

List of contents

Introduction	1
Aim of the work	3
Review of literature	
Mitochondria	4
Mitochondrial ultrastructure	5
Function of the mitochondria	9
Mitochondrial factory	12
The respiratory chain and oxidative phosphorylation.	14
Citric acid cycle	20
Energy formation from lipids	24
Mitochondrial genetics	33
Patterns of genetics mitochondrial disorders	39
Mitochondrial diseases	42
Clinical presentation of mitochondrial diseases	47
Diagnosis of mitochondrial disorders	56
Management of mitochondrial diseases	61
Chronic liver disease	67
Hepatic histology	69
Classification	72
Diagnostic considerations	74
Clinical presentation	74
Management of chronic liver disease	79
Chronic liver diseases and mitochondria	
Hepatitis C	87
Wilson's disease	100
Reye's syndrome	113
Diseases of iron metabolism	115

Hydrophobic bile acid toxicity	117
Porphyria cutanea Tarda	118
Non-Alcoholic steatohepatitis	119
Hepatic mitochondria toxicity due to specific drugs	122
Subjects and methods	125
Results	132
Discussion	192
Summary	213
Conclusion & Recommendations	217
References	219
Arabic Summary	

List Of Abbreviations

AAA	aromatic amino acids
Acetyl coA	Acetyl coenzyme A
ADP	adenosine diphosphate
AIF	apoptosis-inducing factor.
a-KGDH	a-ketoglutarate dehydrogenase.
ANA	Anti-nuclear antibody
ANT	adenine nucleotide translocator
ASMA	Anti-smooth muscle antibody
ATP	adenosine triphosphate
B	blood
BCAA	branched chain amino acid
CHCV	Chronic hepatitis C virus infection.
COPD	chronic obstructive pulmonary disease
coQ 10	Coenzyme Q 10
COX	cytochrome oxidase
CPT-I	carnitine palmitoyl transferase-I
CPT-II	carnitine palmitoyl transferase-II
CSF	Cerebrospinal fluid
CTLs	Cytotoxic T lymphocytes.
DEXA	dual energy X-ray absorptionmetry
DNA	Deoxyribonucleic acid
eALA	erythroid aminolevulinic acid synthase.
EFA	essential fatty acid
ER	Endoplasmic reticulum.
ETC	electron transport chain
FAO	Fatty acid oxidation.
FIAU	Fialuridine

GH	growth hormone
GSH	Glutathione.
H strand	Heavy strand of mitochondrial DNA
HAI	histological activity index
HCC	Hepatocellular carcinoma.
hCTR	human copper transporter.
HCV	hepatitis C virus
HIV	Human immune deficiency virus
IDH	isocitrate dehydrogenase
IGF-I	insulin like growth factor
IRE	iron-responsive element
L strand	light strand of mitochondrial DNA
L/P	Lactate/Pyruvate
LCHAD	L-3-hydroxyacyl-coA dehydrogenase
LCT	long chain fatty acids
LEC	long evans cinnamon.
LHON	Leber's hereditary optic neuropathy
LKM	Liver kidney microsomal antibodies.
MCAD	medium chain acyl-CoA dehydrogenase
MCT	medium chain fatty acids
MDA	Malondialdehyde acid.
MEHMO	Mental Retardation, Epileptic Seizures, Hypogenitalism, Microcephaly, Obesity.
MELAS	Mitochondrial Encephalopathy, Lactic Acidosis and Stroke like Episodes.
MERRF	Myoclonic epilepsy and ragged red fiber disease
MEXG	monoethyl-glycinexylidide
MHC	major histocompatibility complex.
MNGIE	Mitochondrial neurogastro-intestinal

	encephalo-myopathy.
mtDNA	mitochondrial DNA
NARP	Neuropathy, Ataxia and Retinitis Pigmentosa Syndrome.
NASH	Non alcoholic steatohepatitis.
nDNA	Nuclear DNA
OXPPOS	oxidative phosphorylation
PBC	Primary biliary cirrhosis.
PDH	Pyruvate dehydrogenase
PEM	protein energy malnutrition
Pi	inorganic phosphate
PPG	phenylpropionylglycine
RDI	recommended daily intake
REE	resting energy expenditure
RNA	Ribonucleic acid
ROS	Reactive oxygen species.
rRNA	Ribosomal Ribonucleic acid
RTA	Renal tubular acidosis.
SCAD	short-chain acyl-CoA dehydrogenase
SOD	superoxide dismutase.
TBK	total body potassium
TBN	total body nitrogen
TCA	Tricarboxylic acid cycle
TEF	Trifunctional protein
TPGS	tochopherol polyethyleneglycol-1000 succinate
tRNA	Transcriptive ribo nucleic acid.
U	urine
VLCAD	Very long-chain acyl-CoA dehydrogenase

List of Tables

	page
Table (1): Phenotypes observed in fat oxidation disorders.	27
Table (2): Diagnostic Approaches to Defects of Fatty - acid Oxidation	31
Table (3): Initial laboratory evaluation	57
Table (4): Secondary laboratory evaluation	57
Table (5): Tertiary laboratory testing	58
Table (6): Histological activity index (HAI)	70
Table (7): Correlation of HAI score (excluding fibrosis) and diagnosis in chronic hepatitis.	71
Table (8): Scoring system for staging of chronic hepatitis on the basis of fibrosis and architectural alteration	71
Table (9): Classification of chronic hepatitis.	72
Table (10): History relevant points in the differential diagnosis of chronic hepatitis.	77
Table (11): Nutritional management in chronic liver disease.	82
Table (12): Modes of presentation of Wilson's disease	110
Table (13): Prognostic index in acute liver failure in Wilson's disease.	110
Table (14): Age and liver functions tests in the three groups	132
Table (15): Comparison between the three groups as regards hepatosplenomegaly	133
Table (16): Comparison between the three groups as regards clinical data.	134
Table (17a): Number and percentage of chronic liver disease patients with disturbed hepatic architecture	137

Table (17b):	Comparison among the patients of the three groups as regards the presence of disturbed hepatic architecture.	137
Table (17c):	Comparison between the patients with Wilson's disease versus patients with either chronic hepatitis C or other chronic liver diseases as regards the presence of disturbed hepatic architecture.	137
Table (17d):	Comparison between the patients with chronic hepatitis C versus patients with either Wilson's disease or other chronic liver diseases as regards the presence of disturbed hepatic architecture.	137
Table (18a):	The number and percentage of chronic liver disease patients with portal tract fibrosis.	140
Table (18b):	Comparison between the three groups as regards the number of patients with portal tract fibrosis	140
Table (18c):	Comparison between the patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards portal tract fibrosis.	140
Table (18d):	Comparison between the patients with chronic hepatitis C versus those with Wilson's disease or other chronic liver disease as regards portal tract fibrosis	140
Table (19a):	The number and percentage of chronic liver disease patients with portal tract inflammation.	143
Table (19b):	Comparison between the three groups as regards the number of patients with portal tract inflammation.	143
Table (19c):	Comparison between the number of patients with Wilson's disease versus those with	143

	chronic HCV or other chronic liver disease as regards portal tract inflammation	
Table (19d):	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards portal tract inflammation	143
Table (20a):	The number of chronic liver disease patients with disrupted limiting plate.	146
Table (20b):	Comparison between the three groups as regards the number of patients with disrupted limiting plate.	146
Table (20c):	Comparison between the number of patients with Wilson's disease versus those with chronic hepatitis C or with other chronic liver disease as regards having a disrupted limiting plate.	146
Table (20d):	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or with other chronic liver disease as regards having a disrupted limiting plate	146
Table (21a):	The number of chronic liver disease patients with hepatocyte ballooning	149
Table (21b):	Comparison between the three groups as regards the number of patients with hepatocyte ballooning	149
Table (21c):	Comparison between the number of patients with Wilson's disease who have hepatocyte ballooning versus those with chronic HCV or other chronic liver disease.	149
Table(21d):	Comparison between patients with chronic hepatitis C versus those with Wilson's disease or other chronic liver disease as regards hepatocyte ballooning	149

Table (22a)	The number of chronic liver disease patients with liver cirrhosis	152
Table (22b):	Comparison between the three groups as regards the number of patients with hepatic cirrhosis	152
Table (22c):	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards hepatic cirrhosis.	152
Table (22d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards hepatic cirrhosis	152
Table (23a):	The number of chronic liver disease patients with micro-vesicular steatosis	155
Table (23b)	Comparison between the three groups as regards the number of patients with micro-vesicular steatosis	155
Table (23c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards micro-vesicular steatosis.	155
Table (23d)	comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards micro-vesicular steatosis	155
Table (24a)	The number of chronic liver disease patients with macro-vesicular steatosis.	158
Table (24b)	Comparison between the three groups as regards the number of patients with macrovesicular steatosis	158
Table (24c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver diseases	158

	as regards macrovesicular steatosis.	
Table (24d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver diseases as regards macrovesicular steatosis	158
Table (25a)	The number of chronic liver disease patients with mitochondrial pleomorphism	162
Table (25b)	Comparison between the three groups as regards the number of patients with mitochondrial pleomorphism	162
Table (25c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards mitochondrial pleomorphism	162
Table (25d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards mitochondrial pleomorphism	162
Table (26a)	The number of chronic liver disease patients with enlarged mitochondria	165
Table (26b)	Comparison between the three groups as regards the number of patients with enlarged mitochondria	165
Table (26c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards enlarged mitochondria.	165
Table (26d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards enlarged mitochondria	165
Table (27a):	The number and percentage of chronic liver disease patients with mitochondrial dense matriceal granules.	168

Table (27b):	Comparison between the three groups as regards the number of patients with mitochondrial dense matriceal granules.	168
Table (27c):	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards the presence of mitochondrial dense matriceal granules.	168
Table (27d):	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards the presence of mitochondrial dense matriceal granules.	168
Table (28a)	The number of chronic liver disease patients with degenerated mitochondrial cristae.	171
Table (28b)	Comparison between the three groups as regards the number of patients with degenerated mitochondrial cristae	171
Table (28c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards degenerated mitochondrial cristae.	171
Table (28d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards degenerated mitochondrial cristae	171
Table (29a)	The number of chronic liver disease patients with widened inter-cristal space	174
Table (29b)	Comparison between the three groups as regards the number of patients with widened inter-cristal space.	174
Table (29c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as	174

	regards having a widened inter-cristal space	
Table (29d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards having a widened inter-cristal space	174
Table (30a)	The number and percentage of chronic liver disease patients with lysosomal enlargement	177
Table (30b)	Comparison between the three groups as regards the number of patients with lysosomal enlargement.	177
Table (30c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards the presence of lysosomal enlargement.	177
Table (30d)	Comparison between the number of patients with chronic HCV versus those with Wilson's disease or other chronic liver disease as regards the presence of lysosomal enlargement.	177
Table (31a)	The number of chronic liver disease patients with dilated and vesiculated endoplasmic reticulum.	180
Table (31b)	Comparison between the three groups as regards the number of patients with dilated and vesiculated endoplasmic reticulum.	180
Table (31c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards the presence of dilated and vesiculated endoplasmic reticulum.	180
Table (31d)	Comparison between the number of patients with chronic HCV versus those with Wilson's	180

	disease or other chronic liver disease as regards the presence of dilated and vesiculated endoplasmic reticulum.	
Table (32a)	The number of chronic liver disease patients with mitochondrial DNA deletion.	184
Table (32b)	Comparison between the three groups as regards the number of patients with mitochondrial DNA deletions.	184
Table (32c)	Comparison between the number of patients with Wilson's disease versus those with chronic HCV or other chronic liver disease as regards mitochondrial DNA deletions.	184
Table (32d)	Comparison between the number of patients with chronic hepatitis C versus those with Wilson's disease or other chronic liver disease as regards mitochondrial DNA deletions.	184
Table (33)	Mitochondrial affection scoring system.	186
Table (34)	Comparison between the patients with different mitochondrial affection as regards the presence of hepatic Steatosis.	187

List of Figures

		page
Figure (1):	Mitochondrial structure in relation to its' function.	10
Figure (2):	Energy extraction from mitochondria.	14
Figure (3):	The Flow of electrons during oxidative phosphorylation.	15
Figure (4):	Schematic diagram of the respiratory chain.	17
Figure (5):	Different stages of the chemical reactions in the citric acid cycle.	21
Figure (6):	Fatty-acid metabolism and ketogenesis.	26
Figure (7):	The mitochondrial DNA.	35
Figure (8):	Interaction between Genes Encoded by Nuclear DNA and Those Encoded by Mitochondrial DNA in Oxidative-Phosphorylation.	41
Figure (9):	Clinical features of mitochondrial disease.	49
Figure (10):	Possible mechanisms of HCV-mediated mitochondrial dysfunction.	94
Figure (11):	Liver enlargement in the three groups of patients	133
Figure (12):	Splenomegaly in the three groups of patients	133
Figure (13a):	The number of chronic liver disease patients with disturbed hepatic architecture	138
Figure (13b):	Hepatic architecture in patients of the three groups	138
Figure (13c):	Hepatic architecture in patients with Wilson's disease versus patients with chronic HCV or other CLD	138
Figure (13d):	Hepatic architecture in patients with chronic HCV versus those with Wilson's disease or	138

	other CLD.	
Figure (14a):	Number of chronic liver disease patients with portal tract fibrosis	141
Figure (14b):	Portal tract fibrosis in patients of the three groups	141
Figure (14c):	Portal tract fibrosis in patients with Wilson's disease versus patients with chronic HCV or other CLD	141
Figure (14d):	Portal tract fibrosis in patients with chronic HCV versus patients with Wilson's disease or other CLD.	141
Figure (15a):	Number of chronic liver disease patients with portal tract inflammation.	144
Figure (15b):	Portal tract inflammation in patients of the three groups	144
Figure (15c):	Portal tract inflammation in patients with Wilson's disease versus patients with chronics HCV or other CLD.	144
Figure (15d):	Portal tract inflammation in patients with chronic HCV versus patients with Wilson's disease or other CLD.	144
Figure (16a):	The number of chronic liver disease patients with disrupted limiting plate.	147
Figure (16b):	Disruption of the limiting plate among the patients of the three groups	147
Figure (16c):	Disruption of the limiting plate in patients with Wilson's disease versus patients with chronic HCV or other CLD.	147
Figure (16d):	Disruption of the limiting plate in patients with chronic HCV versus patients with Wilson's disease or other CLD.	147
Figure (17a):	The number of chronic liver disease patients with hepatocyte ballooning.	150